A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma

BMC Cancer

Madhuri Bhandaru¹  Gholamreza Safaee Ardekani¹  Guohong Zhang¹  Magdalena Martinka²  Kevin J McElwee¹  Gang Li¹  Anand Rotte¹ 

[1] Skin Cancer Biology Laboratory, Department of Dermatology and Skin Science, University of British Columbia, Research Pavilion, 828 West, 10th Avenue, Vancouver, BC V5Z 1 L8, Canada

[2] Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada

关键词: Patient survival;    AJCC;    Prognosis;    Melanoma;    Braf;    p300;   

Others  :  858731
DOI  :  10.1186/1471-2407-14-398

 received in 2013-11-10, accepted in 2014-05-29,  发布年份 2014

【 摘 要 】

Background

To date only a handful of drugs are available for the treatment of melanoma. Among them vemurafenib, a Braf^V600E specific inhibitor, showed promising results in terms of response rate and increase in median survival time. However, its effectiveness is limited by development of resistance and the search for additional drugs for melanoma treatment is ongoing. The present study was performed to analyze the correlation between Braf expression and the expression of p300, a known down stream target of the mitogen activated protein kinase (MAPK) pathway, which was recently shown by us to be a prognostic marker for melanoma progression and patient survival.

Methods

The expression of Braf and p300 expression were correlated and analyzed by Chi-square test. A total of 327 melanoma patient cases (193 primary melanoma and 134 metastatic melanoma) were used for the study. Classification & regression tree (CRT), Kaplan-Meier, and multivariate Cox regression analysis were used to elucidate the significance of the combination of Braf and p300 expression in the diagnosis and prognosis of melanoma.

Results

Our results demonstrate that Braf expression is inversely correlated with nuclear p300 and positively correlated with cytoplasmic p300 expression. Braf and cytoplasmic p300 were found to be associated with melanoma progression, tumor size and ulceration status. CRT analysis revealed that a combination of Braf and p300 expression (nuclear and cytoplasmic), could be used to distinguish between nevi and melanoma, and primary from metastatic melanoma lesions. The combination of Braf and nuclear p300 was significantly associated with patient survival and nuclear p300 was found to be an independent predictor of patient survival.

Conclusion

Our results indicate a cross-talk between Braf and p300 in melanoma and demonstrate the importance Braf and p300 expression in the diagnosis and prognosis of melanoma.

【 授权许可】

   
2014 Bhandaru et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Miller AJ, Mihm MC Jr: Melanoma. N Engl J Med 2006, 355(1):51-65.
• [2]Rastrelli M, Alaibac M, Stramare R, Chiarion Sileni V, Montesco MC, Vecchiato A, Campana LG, Rossi CR: Melanoma m (zero): diagnosis and therapy. ISRN Dermatol 2013, 2013:616170.
• [3]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
• [4]Turner RM, Bell KJ, Morton RL, Hayen A, Francken AB, Howard K, Armstrong B, Thompson JF, Irwig L: Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. J Clin Oncol 2011, 29(35):4641-4646.
• [5]Bilimoria KY, Raval MV, Bentrem DJ, Wayne JD, Balch CM, Ko CY: National assessment of melanoma care using formally developed quality indicators. J Clin Oncol 2009, 27(32):5445-5451.
• [6]Finn L, Markovic SN, Joseph RW: Therapy for metastatic melanoma: the past, present, and future. BMC Med 2012, 10:23. BioMed Central Full Text
• [7]Safaee Ardekani G, Jafarnejad SM, Khosravi S, Martinka M, Ho V, Li G: Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma. Br J Dermatol 2013, 169(2):320-328.
• [8]Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G: The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One 2012, 7(10):e47054.
• [9]Roth SY, Denu JM, Allis CD: Histone acetyltransferases. Annu Rev Biochem 2001, 70:81-120.
• [10]Rotte A, Bhandaru M, Cheng Y, Sjoestroem C, Martinka M, Li G: Decreased expression of nuclear p300 is associated with disease progression and worse prognosis of melanoma patients. PLoS One 2013, 8(9):e75405.
• [11]Poizat C, Puri PL, Bai Y, Kedes L: Phosphorylation-dependent degradation of p300 by doxorubicin-activated p38 mitogen-activated protein kinase in cardiac cells. Mol Cell Biol 2005, 25(7):2673-2687.
• [12]Wang SA, Hung CY, Chuang JY, Chang WC, Hsu TI, Hung JJ: Phosphorylation of p300 increases its protein degradation to enhance the lung cancer progression. Biochim Biophys Acta 2014, 1843(6):1135-1149.
• [13]Zhang Z, Chen G, Cheng Y, Martinka M, Li G: Prognostic significance of RUNX3 expression in human melanoma. Cancer 2011, 117(12):2719-2727.
• [14]Chen G, Cheng Y, Zhang Z, Martinka M, Li G: Cytoplasmic Skp2 expression is increased in human melanoma and correlated with patient survival. PLoS One 2011, 6(2):e17578.
• [15]Remmele W, Stegner HE: [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 1987, 8(3):138-140.
• [16]Zhang G, Li G: Novel multiple markers to distinguish melanoma from dysplastic nevi. PLoS One 2012, 7(9):e45037.
• [17]Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Eggermont AM DS, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27(36):6199-6206.
• [18]Pellacani G, Longo C, Ferrara G, Cesinaro AM, Bassoli S, Guitera P, Menzies SW, Seidenari S: Spitz nevi: In vivo confocal microscopic features, dermatoscopic aspects, histopathologic correlates, and diagnostic significance. J Am Acad Dermatol 2009, 60(2):236-247.
• [19]Duffy K, Grossman D: The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management. J Am Acad Dermatol 2012, 67(1):19 e11-12. quiz 31–12
• [20]Duffy K, Grossman D: The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects. J Am Acad Dermatol 2012, 67(1):1 e1-16. quiz 17–18
• [21]Rabkin MS: The limited specificity of histological examination in the diagnosis of dysplastic nevi. J Cutan Pathol 2008, 35(Suppl 2):20-23.
• [22]Camp RL, Neumeister V, Rimm DL: A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol 2008, 26(34):5630-5637.
• [23]Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AMM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, for the BRIM-3 Study Group: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364(26):2507-2516.
• [24]Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O’Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363(9):809-819.
• [25]Kudchadkar R, Paraiso KH, Smalley KS: Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J 2012, 18(2):124-131.
• [26]Iyer NG, Ozdag H, Caldas C: p300/CBP and cancer. Oncogene 2004, 23(24):4225-4231.
• [27]Reed SH: Nucleotide excision repair in chromatin: damage removal at the drop of a HAT. DNA Repair (Amst) 2011, 10(7):734-742.
• [28]Tillhon M, Cazzalini O, Nardo T, Necchi D, Sommatis S, Stivala LA, Scovassi AI, Prosperi E: p300/CBP acetyl transferases interact with and acetylate the nucleotide excision repair factor XPG. DNA Repair (Amst) 2012, 11(10):844-852.
• [29]Chen G, Cheng Y, Tang Y, Martinka M, Li G: Role of Tip60 in human melanoma cell migration, metastasis, and patient survival. J Invest Dermatol 2012, 132(11):2632-2641.
• [30]Giannini G, Cabri W, Fattorusso C, Rodriquez M: Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Med Chem 2012, 4(11):1439-1460.
• [31]Haigentz M Jr, Kim M, Sarta C, Lin J, Keresztes RS, Culliney B, Gaba AG, Smith RV, Shapiro GI, Chirieac LR Mariadason JM, Belbin TJ, Greally JM, Wright JJ, Haddadf RI: Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncol 2012, 48(12):1281-1288.
• [32]Murakami T, Sato A, Chun NA, Hara M, Naito Y, Kobayashi Y, Kano Y, Ohtsuki M, Furukawa Y, Kobayashi E: Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma. J Invest Dermatol 2008, 128(6):1506-1516.
• [33]Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, Bowcock AM, Harbour JW: Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res 2012, 18(2):408-416.
• [34]Dekker FJ, Haisma HJ: Histone acetyl transferases as emerging drug targets. Drug Discov Today 2009, 14(19–20):942-948.
• [35]Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR: A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs 2013, 31(1):115-125.
• [36]Wang QE, Han C, Zhao R, Wani G, Zhu Q, Gong L, Battu A, Racoma I, Sharma N, Wani AA: p38 MAPK- and Akt-mediated p300 phosphorylation regulates its degradation to facilitate nucleotide excision repair. Nucleic Acids Res 2013, 41(3):1722-1733.
• [37]Chen J, Li Q: Life and death of transcriptional co-activator p300. Epigenetics 2011, 6(8):957-961.
• [38]Bricambert J, Miranda J, Benhamed F, Girard J, Postic C, Dentin R: Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic steatosis in mice. J Clin Invest 2010, 120(12):4316-4331.
• [39]Yuan LW, Gambee JE: Phosphorylation of p300 at serine 89 by protein kinase C. J Biol Chem 2000, 275(52):40946-40951.
• [40]Chen J, Halappanavar SS, St-Germain JR, Tsang BK, Li Q: Role of Akt/protein kinase B in the activity of transcriptional coactivator p300. Cell Mol Life Sci 2004, 61(13):1675-1683.
• [41]Huang WC, Chen CC: Akt phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity. Mol Cell Biol 2005, 25(15):6592-6602.
• [42]Liu Y, Denlinger CE, Rundall BK, Smith PW, Jones DR: Suberoylanilide hydroxamic acid induces Akt-mediated phosphorylation of p300, which promotes acetylation and transcriptional activation of RelA/p65. J Biol Chem 2006, 281(42):31359-31368.
• [43]Chen YJ, Wang YN, Chang WC: ERK2-mediated C-terminal serine phosphorylation of p300 is vital to the regulation of epidermal growth factor-induced keratin 16 gene expression. J Biol Chem 2007, 282(37):27215-27228.